BURLINGTON, Mass., Nov. 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) are increasingly scrutinizing the cost to the healthcare system of anti-vascular endothelial growth factor (VEGF) agents labeled for wet age-related macular degeneration (AMD). In fact, legislation has recently been enacted in France and Italy to allow for off-label use of Roche's Avastin, which is priced significantly lower than other anti-VEGF drugs when compounded for ophthalmic administration. The majority of surveyed retinal specialists in these markets anticipate these legislative decrees to at least moderately increase their prescribing of Avastin for wet AMD.
No comments:
Post a Comment